Maria Victoria Mateos

Summary

Affiliation: Universidad de Salamanca
Country: Spain

Publications

  1. doi request reprint Novel generation of agents with proven clinical activity in multiple myeloma
    Maria Victoria Mateos
    Haematology Department, University Hospital of Salamanca, Cancer Research Center IBMCC CSIC, University of Salamanca, Institute of Biomedical Research of Salamanca IBSAL, Spain Electronic address
    Semin Oncol 40:618-33. 2013
  2. doi request reprint New approaches to smoldering myeloma
    Maria Victoria Mateos
    Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Instituto de Biologia Molecular y Celular del Cancer, Universidad de Salamanca Consejo Superior de Investigaciones Cientificas, Salamanca, Spain
    Curr Hematol Malig Rep 8:270-6. 2013
  3. doi request reprint How to maintain patients on long-term therapy: understanding the profile and kinetics of adverse events
    Maria Victoria Mateos
    Hematology Department, University Hospital of Salamanca, Salamanca, Spain
    Leuk Res 36:S35-43. 2012
  4. ncbi request reprint Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial
    Maria Victoria Mateos
    Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Instituto de Biología Molecular y Celular del Cáncer Universidad de Salamanca Consejo Superior de Investigaciones Científicas, Salamanca, Spain
    Blood 120:2581-8. 2012
  5. doi request reprint Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myelom
    Maria Victoria Mateos
    University Hospital of Salamanca, Salamanca, Spain
    Lancet Oncol 11:934-41. 2010
  6. doi request reprint Role of bortezomib for the treatment of previously untreated multiple myeloma
    Maria Victoria Mateos
    Hematology Department, University Hospital of Salamanca, Salamanca, Spain
    Expert Rev Hematol 1:17-28. 2008
  7. doi request reprint Management of treatment-related adverse events in patients with multiple myeloma
    Maria Victoria Mateos
    Haematology Department, University Hospital of Salamanca, Salamanca, Spain
    Cancer Treat Rev 36:S24-32. 2010
  8. doi request reprint Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance
    Maria Victoria Mateos
    University Hospital of Salamanca, Salamanca, Spain
    Blood 118:4547-53. 2011
  9. doi request reprint Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma
    Maria Victoria Mateos
    Departamento de Hematologia, Hospital Universitario de Salamanca, Salamanca, Spain
    Clin Cancer Res 16:3260-9. 2010
  10. doi request reprint Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma
    Jesus F San Miguel
    Hospital Universitario Salamanca, Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain
    J Clin Oncol 31:448-55. 2013

Collaborators

Detail Information

Publications34

  1. doi request reprint Novel generation of agents with proven clinical activity in multiple myeloma
    Maria Victoria Mateos
    Haematology Department, University Hospital of Salamanca, Cancer Research Center IBMCC CSIC, University of Salamanca, Institute of Biomedical Research of Salamanca IBSAL, Spain Electronic address
    Semin Oncol 40:618-33. 2013
    ....
  2. doi request reprint New approaches to smoldering myeloma
    Maria Victoria Mateos
    Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Instituto de Biologia Molecular y Celular del Cancer, Universidad de Salamanca Consejo Superior de Investigaciones Cientificas, Salamanca, Spain
    Curr Hematol Malig Rep 8:270-6. 2013
    ....
  3. doi request reprint How to maintain patients on long-term therapy: understanding the profile and kinetics of adverse events
    Maria Victoria Mateos
    Hematology Department, University Hospital of Salamanca, Salamanca, Spain
    Leuk Res 36:S35-43. 2012
    ..AEs are generally transient, occurring early in the course of treatment, providing evidence for the feasibility of continuous therapy...
  4. ncbi request reprint Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial
    Maria Victoria Mateos
    Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Instituto de Biología Molecular y Celular del Cáncer Universidad de Salamanca Consejo Superior de Investigaciones Científicas, Salamanca, Spain
    Blood 120:2581-8. 2012
    ..In summary, these maintenance regimens result in a significant increase in CR rate, remarkably long PFS, and acceptable toxicity profile. The trial is registered at www.clinicaltrials.gov as NCT00443235...
  5. doi request reprint Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myelom
    Maria Victoria Mateos
    University Hospital of Salamanca, Salamanca, Spain
    Lancet Oncol 11:934-41. 2010
    ..We investigated a novel and less intensive bortezomib-based regimen to maintain efficacy and to reduce toxic effects...
  6. doi request reprint Role of bortezomib for the treatment of previously untreated multiple myeloma
    Maria Victoria Mateos
    Hematology Department, University Hospital of Salamanca, Salamanca, Spain
    Expert Rev Hematol 1:17-28. 2008
    ..These results allow bortezomib-based combination therapy to be established as key options for patients with previously untreated multiple myeloma...
  7. doi request reprint Management of treatment-related adverse events in patients with multiple myeloma
    Maria Victoria Mateos
    Haematology Department, University Hospital of Salamanca, Salamanca, Spain
    Cancer Treat Rev 36:S24-32. 2010
    ..We further review the management of these adverse events with a view to delivering optimal therapeutic outcomes in patients with newly diagnosed and relapsed and/or refractory multiple myeloma...
  8. doi request reprint Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance
    Maria Victoria Mateos
    University Hospital of Salamanca, Salamanca, Spain
    Blood 118:4547-53. 2011
    ..02). The present schema does not overcome the negative prognosis of high-risk CAs and nonhyperdiploidy. This trial was registered with www.ClinicalTrials.gov as NCT00443235...
  9. doi request reprint Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma
    Maria Victoria Mateos
    Departamento de Hematologia, Hospital Universitario de Salamanca, Salamanca, Spain
    Clin Cancer Res 16:3260-9. 2010
    ..This trial evaluated the antitumor activity and safety of the marine-derived cyclodepsipeptide plitidepsin in patients with relapsed/refractory multiple myeloma...
  10. doi request reprint Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma
    Jesus F San Miguel
    Hospital Universitario Salamanca, Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain
    J Clin Oncol 31:448-55. 2013
    ....
  11. doi request reprint Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial
    Maria Victoria Mateos
    Hospital Universitario de Salamanca, Paseo San Vicente 58 182, 37007 Salamanca, Spain
    J Clin Oncol 28:2259-66. 2010
    ....
  12. doi request reprint Multiparameter flow cytometry evaluation of plasma cell DNA content and proliferation in 595 transplant-eligible patients with myeloma included in the Spanish GEM2000 and GEM2005<65y trials
    Bruno Paiva
    Hospital Universitario de Salamanca, Spain
    Am J Pathol 181:1870-8. 2012
    ..NH-MM and a high proliferation index assessed by multiparameter flow cytometry remain as independent prognostic factors in MM, but the latter may be overcome by incorporating novel agents in the HDT/ASCT setting...
  13. doi request reprint Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma
    Bruno Paiva
    Hospital Universitario de Salamanca, Salamanca, Spain
    J Clin Oncol 29:1627-33. 2011
    ..To investigate the impact of immunophenotypic response (IR) versus complete response (CR) and CR plus normal serum free light chain (sFLC) ratio (stringent CR) in elderly patients with multiple myeloma (MM) treated with novel agents...
  14. doi request reprint High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma
    Bruno Paiva
    Hospital Universitario de Salamanca, Spain
    Blood 119:687-91. 2012
    ..0; P = .005) were the only independent factors that predicted unsustained CR. Thus, these 2 parameters may help to identify patients in CR at risk of early progression after HDT/ASCT in whom novel treatments should be investigated...
  15. doi request reprint The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients
    Bruno Paiva
    Hospital Universitario de Salamanca, Salamanca, Spain
    Blood 114:4369-72. 2009
    ..This trial was registered at www.clinicaltrials.gov as NCT00560053...
  16. doi request reprint Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression
    Maria Victoria Mateos
    Hospital Universitario de Salamanca, Salamanca, Spain
    Haematologica 93:560-5. 2008
    ..Here, we report updated time-to-events data and the impact of poor prognosis factors on outcome...
  17. doi request reprint Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma
    Maria Victoria Mateos
    Hospital Universitario de Salamanca, Instituto de Biologia Molecular y Celular del Cancer, Universidad de Salamanca Consejo Superior de Investigaciones Cientificas, Salamanca, Spain
    N Engl J Med 369:438-47. 2013
    ..For patients with smoldering multiple myeloma, the standard of care is observation until symptoms develop. However, this approach does not identify high-risk patients who may benefit from early intervention...
  18. doi request reprint Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience
    Adrian Alegre
    Hematology Department, Hospital Universitario de la Princesa, Madrid, Spain
    Leuk Lymphoma 53:1714-21. 2012
    ..gov: NCT00420849)...
  19. doi request reprint The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells
    Lucía López-Corral
    Servicio de Hematologia, Hospital Universitario, Universidad de Salamanca, Salamanca, Spain
    Clin Cancer Res 17:1692-700. 2011
    ..Our aim was to investigate in depth the level of clonal heterogeneity of recurrent genetic abnormalities in these conditions...
  20. pmc Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients
    Bruno Paiva
    Hospital Universitario de Salamanca, Paseo de San Vicente 58 182, 37007 Salamanca, Spain
    Haematologica 94:1599-602. 2009
    ..clinicaltrials.gov identifier: NCT00560053)...
  21. doi request reprint Novel agents derived from the currently approved treatments for MM: novel proteasome inhibitors and novel IMIDs
    Enrique M Ocio
    University of Salamanca, University Hospital and Cancer Research Center, Department of Hematology, Salamanca, Spain
    Expert Opin Investig Drugs 21:1075-87. 2012
    ....
  22. doi request reprint Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival
    Juan Jose Lahuerta
    Hospital Universitario de Salamanca, Salamanca, Spain
    J Clin Oncol 26:5775-82. 2008
    ..We evaluated the prognostic influence on event-free survival (EFS) and overall survival (OS) of these responses pre- and post-transplantation in newly diagnosed patients with MM...
  23. doi request reprint The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis
    Bruno Paiva
    Hospital Universitario de Salamanca, Paseo de San Vicente 58 182, Salamanca, Spain
    Blood 117:3613-6. 2011
    ..01). MFC immunophenotyping could be clinically useful for the demonstration of PC clonality in AL and for the prognostication of patients with AL...
  24. pmc Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry
    Roberto J Pessoa de Magalhães
    Hospital Universitario de Salamanca, Salamanca, Spain
    Haematologica 98:79-86. 2013
    ....
  25. doi request reprint Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
    Jesus F San Miguel
    Hospital Universitario Salamanca, CIC, IBMCC USAL CSIC, Salamanca, Spain
    N Engl J Med 359:906-17. 2008
    ..This phase 3 study compared the use of melphalan and prednisone with or without bortezomib in previously untreated patients with multiple myeloma who were ineligible for high-dose therapy...
  26. ncbi request reprint Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy?
    Maria Victoria Mateos
    Servicio de Hematologia, Hospital Universitario de Salamanca, Salamanca, Spain
    Br J Haematol 140:324-6. 2008
    ..Consequently, G-CSF could be effective in preventing further neutropenia-related complications without compromising treatment efficacy in MM patients with lenalidomide-induced neutropenia...
  27. doi request reprint Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma
    Maria E Sarasquete
    Servicio de Hematologia, Hospital Universitario de Salamanca e Instituto Biosanitario de Salamanca IBSAL, Universidad de Salamanca, Salamanca, Spain Centro de Investigación del Cáncer de Salamanca, Salamanca, Spain
    Br J Haematol 163:223-34. 2013
    ..61% at 5 years; P = 0·003). This study demonstrates that quantitative PCR is a robust, accurate and feasible technique for implementing in the daily routine as a surrogate for GEP-arrays. ..
  28. pmc Genomic analysis of high-risk smoldering multiple myeloma
    Lucía López-Corral
    Servicio de Hematología del Hospital Universitario de Salamanca y Centro de Investigación del Cáncer IBMCC USAl CIC, Universidad de Salamanca, Salamanca, Spain
    Haematologica 97:1439-43. 2012
    ..These findings suggest that gene expression profiling is a valuable technique to identify smoldering myeloma patients with high risk of progression. (Clinical Trials NCT00443235)...
  29. doi request reprint New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings
    Enrique M Ocio
    Servicio de Hematologia, Hospital Universitario de Salamanca, Salamanca, Spain
    Lancet Oncol 9:1157-65. 2008
    ..Unfortunately, the single-agent clinical activity of most of these new drugs has been limited; nevertheless, their effectiveness might be enhanced by their rational combination with each other or with conventional agents...
  30. doi request reprint Multiple myeloma patients have a specific serum metabolomic profile that changes after achieving complete remission
    Leonor Puchades-Carrasco
    Structural Biochemistry Laboratory, Centro de Investigacion Principe Felipe, Valencia, Spain
    Clin Cancer Res 19:4770-9. 2013
    ..In this study, we aimed to evaluate the potential of metabolomics by (1)H-NMR to provide information on metabolic profiles that could be useful in the management of multiple myeloma...
  31. ncbi request reprint New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells
    Ernesto Pérez-Persona
    Department of Hematology, University Hospital, Salamanca, Spain
    Blood 110:2586-92. 2007
    ..001). Our results show that multiparameter FC evaluation of BMPC at diagnosis is a valuable tool that could help to individualize the follow-up strategy for MGUS and SMM patients...
  32. doi request reprint Initial treatment of transplant-ineligible patients in multiple myeloma
    Maria Victoria Mateos
    Hospital Universitario de Salamanca, Paseo San Vicente 58 182, 37007 Salamanca, Spain
    Expert Rev Hematol 7:67-77. 2014
    ..Data indicate that prolonged treatment extends the progression-free survival. In summary, this group requires individualized and dose-modified regimens to improve tolerability and efficacy, while maintaining their quality of life. ..
  33. ncbi request reprint [Multiple myeloma]
    Ramon Garcia-Sanz
    Servicio de Hematologia, Hospital Universitario de Salamanca, Centro de Investigacion del Cancer, Salamanca, Espana
    Med Clin (Barc) 129:104-15. 2007
    ....
  34. ncbi request reprint Medium-term results of percutaneous vertebroplasty in multiple myeloma
    Luis Ramos
    Department of Orthopaedic Surgery, University Hospital of Salamanca, Salamanca, Spain
    Eur J Haematol 77:7-13. 2006
    ..PVP is associated with early clinical improvement of pain and function and can be maintained after a long follow-up without major procedure-related complications...